Story thread · 10 reports / 7 sources
STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
statnews.com · 11d
How the coverage leans
Across 7 sources · syndicated copies counted once
An FDA advisory panel recommended use of an experimental Replimune treatment for advanced melanoma that the agency has rejected twice
First report: FDA staff say Replimune's melanoma trial failed to prove RP1 works — endpts.com, 14d
The coverage
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.